Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Vir Biotechnology VIR is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock ...

Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $12.37 million for the quarter, compared to analyst estimates of $8.14 ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago. These ...

5 analysts have expressed a variety of opinions on Vir Biotechnology VIR over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

VIR insiders have traded $VIR stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales. Here’s a ...

Dr Rajesh Gupta, vice president, global health portfolio and public-private partnerships at Vir Biotechnology, said: “COVID-19 reinforced the ever-present global threat of infectious diseases ...